Fifth Third Bancorp
DNLI icon

Fifth Third Bancorp’s Denali Therapeutics DNLI Stock Holding History

Fifth Third Bancorp’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.7K Buy
3,019
+172
+6% +$3.53K ﹤0.01% 3060
2026
Q1 		$54.7K Buy
+2,847
New +$56.6K ﹤0.01% 3160

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's DNLI Position: Q2 2026 in Review

Fifth Third Bancorp increased its Denali Therapeutics (DNLI) stake by 6% in Q2 2026, buying an estimated $3.53K and bringing the position to 3,019 shares worth $77.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Fifth Third Bancorp first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Fifth Third Bancorp held 3,019 shares of Denali Therapeutics worth $77.7K as of Q2 2026.
  • Fifth Third Bancorp bought 172 Denali Therapeutics shares in Q2 2026, an estimated $3.53K.
  • Denali Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3060 holding.
  • Fifth Third Bancorp first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.